Hexon-modified Recombinant E1-deleted Adenovirus Vectors as Dual Specificity Vaccine Carriers for Influenza Virus

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 696-706

  Zhou, Dongming ^a,b   Wu, Te Lang ^a,c   Emmer, Kristel L ^a,c   Kurupati, Raj ^a   Tuyishime, Steven ^a,c   Li, Yan ^a   Giles Davis, Wynetta ^a   Zhou, Xiangyang ^a   Xiang, Zhiquan ^a   Liu, Qin ^a   Ratcliffe, Sarah J ^c   Ertl, Hildegund C J ^a  

^a WISTAR INSTITUTE   (United States)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; GLYCOPROTEIN E1; HEXON PROTEIN; HYBRID PROTEIN; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; EXTRACELLULAR MATRIX; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VIRUS; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS EXPRESSION; VIRUS REPLICATION;

ADENOVIRIDAE; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; PAN;

EID: 84875213190     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.248     Document Type: Article

References (42)

1. Colloca, S, Barnes, E, Folgori, A, Ammendola, V, Capone, S, Cirillo, A et al. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 115ra2.
2. Hansen, SG, Ford, JC, Lewis, MS, Ventura, AB, Hughes, CM, Coyne-Johnson, L et al. (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
3. Kahn, JS, Roberts, A, Weibel, C, Buonocore, L and Rose, JK (2001). Replicationcompetent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75: 11079-11087.
4. Tatsis, N, Fitzgerald, JC, Reyes-Sandoval, A, Harris-McCoy, KC, Hensley, SE, Zhou, D et al. (2007). Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110: 1916-1923.
5. Rupprecht, CE, Wiktor, TJ, Johnston, DH, Hamir, AN, Dietzschold, B, Wunner, WH et al. (1986). Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA 83: 7947-7950.
6. Xiang, ZQ, Yang, Y, Wilson, JM and Ertl, HC (1996). A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219: 220-227.
7. Dintzis, HM, Dintzis, RZ and Vogelstein, B (1976). Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci USA 73: 3671-3675.
8. Xiang, Z, Gao, G, Reyes-Sandoval, A, Cohen, CJ, Li, Y, Bergelson, JM et al. (2002). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76: 2667-2675.
9. Rux, JJ, Kuser, PR and Burnett, RM (2003). Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77: 9553-9566.
10. Xue, F and Burnett, RM (2006). Capsid-like arrays in crystals of chimpanzee adenovirus hexon. J Struct Biol 154: 217-221.
11. Pichla-Gollon, SL, Drinker, M, Zhou, X, Xue, F, Rux, JJ, Gao, GP et al. (2007). Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 81: 1680-1689.
12. Matthews, QL, Fatima, A, Tang, Y, Perry, BA, Tsuruta, Y, Komarova, S et al. (2010). HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS ONE 5: e11815.
13. Worgall, S, Krause, A, Rivara, M, Hee, KK, Vintayen, EV, Hackett, NR et al. (2005). Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281-1289.
14. Fitzgerald, JC, Gao, GP, Reyes-Sandoval, A, Pavlakis, GN, Xiang, ZQ, Wlazlo, AP et al. (2003). A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170: 1416-1422.
15. Abe, S, Okuda, K, Ura, T, Kondo, A, Yoshida, A, Yoshizaki, S et al. (2009). Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med 11: 570-579.
16. Bradley, RR, Lynch, DM, Iampietro, MJ, Borducchi, EN and Barouch, DH (2012). Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 86: 625-629.
17. Pichla-Gollon, SL, Lin, SW, Hensley, SE, Lasaro, MO, Herkenhoff-Haut, L, Drinker, M et al. (2009). Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 83: 5567-5573.
18. Xiang, Z, Li, Y, Cun, A, Yang, W, Ellenberg, S, Switzer, WM et al. (2006). Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerging Infect Dis 12: 1596-1599.
19. Liu, W, Zou, P and Chen, YH (2004). Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93: 131-136.
20. Neirynck, S, Deroo, T, Saelens, X, Vanlandschoot, P, Jou, WM and Fiers, W (1999). A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
21. Zhou, D, Wu, TL, Lasaro, MO, Latimer, BP, Parzych, EM, Bian, A et al. (2010). A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 18: 2182-2189.
22. Ulmer, JB, Donnelly, JJ, Parker, SE, Rhodes, GH, Felgner, PL, Dwarki, VJ et al. (1993). Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
23. Mozdzanowska, K, Feng, J, Eid, M, Kragol, G, Cudic, M, Otvos, L Jr et al. (2003). Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
24. Yang, Y, Li, Q, Ertl, HC and Wilson, JM (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69: 2004-2015.
25. Bachmann, MF, Hengartner, H and Zinkernagel, RM (1995). T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol 25: 3445-3451.
26. Veltrop-Duits, LA, Heemskerk, B, Sombroek, CC, van Vreeswijk, T, Gubbels, S, Toes, RE et al. (2006). Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur J Immunol 36: 2410-2423.
27. Choi, JH, Dekker, J, Schafer, SC, John, J, Whitfill, CE, Petty, CS et al. (2012). Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity. Clin Vaccine Immunol 19: 84-95.
28. Krause, A, Joh, JH, Hackett, NR, Roelvink, PW, Bruder, JT, Wickham, TJ et al. (2006). Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80: 5523-5530.
29. Bayer, W, Tenbusch, M, Lietz, R, Johrden, L, Schimmer, S, Uberla, K et al. (2010). Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J Virol 84: 1967-1976.
30. Hensley, SE, Giles-Davis, W, McCoy, KC, Weninger, W and Ertl, HC (2005). Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 175: 6032-6041.
31. Reyes-Sandoval, A, Fitzgerald, JC, Grant, R, Roy, S, Xiang, ZQ, Li, Y et al. (2004). Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 78: 7392-7399.
32. Barnes, E, Folgori, A, Capone, S, Swadling, L, Aston, S, Kurioka, A et al. (2012). Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra1.
33. Thompson, WW, Comanor, L and Shay, DK (2006). Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 194 (suppl. 2): S82-S91.
34. Fan, J, Liang, X, Horton, MS, Perry, HC, Citron, MP, Heidecker, GJ et al. (2004). Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
35. Carragher, DM, Kaminski, DA, Moquin, A, Hartson, L and Randall, TD (2008). A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168-4176.
36. Gschoesser, C, Almanzar, G, Hainz, U, Ortin, J, Schonitzer, D, Schild, H et al. (2002). CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein. Vaccine 20: 3731-3738.
37. McMichael, AJ, Michie, CA, Gotch, FM, Smith, GL and Moss, B (1986). Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 67 (Pt 4): 719-726.
38. Epstein, SL (2006). Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49-53.
39. Ekiert, DC, Bhabha, G, Elsliger, MA, Friesen, RH, Jongeneelen, M, Throsby, M et al. (2009). Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
40. Ekiert, DC, Friesen, RH, Bhabha, G, Kwaks, T, Jongeneelen, M, Yu, W et al. (2011). A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
41. Wang, TT, Tan, GS, Hai, R, Pica, N, Ngai, L, Ekiert, DC et al. (2010). Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 107: 18979-18984.
42. Zhou, D, Zhou, X, Bian, A, Li, H, Chen, H, Small, JC et al. (2010). An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5: 1775-1785.